Alan Priester, PhD, presented “Emergent Applications of Prostate Cancer Mapping with Artificial Intelligence” during the 7th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on September 22, 2023.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Priester, Alan. “Emergent Applications of Prostate Cancer Mapping with Artificial Intelligence.” September 22, 2023. Accessed Aug 2024. https://grandroundsinurology.com/emergent-applications-of-prostate-cancer-mapping-with-artificial-intelligence/
Emergent Applications of Prostate Cancer Mapping with Artificial Intelligence – Summary
Alan Priester, PhD explores the cutting-edge applications of artificial intelligence (AI) in mapping prostate cancer, emphasizing its transformative potential in precision diagnosis and treatment. Dr. Priester illustrates how AI-driven algorithms analyze vast datasets, offering unprecedented insights into prostate cancer’s spatial and molecular characteristics. These advanced mapping techniques enable the identification of cancerous lesions with remarkable precision, facilitating earlier and more accurate diagnoses.
Moreover, Dr. Priester highlights the role of AI in developing predictive models that forecast disease progression and patient outcomes. These models are instrumental in tailoring individualized treatment plans.
Dr. Priester also addresses the challenges and ethical considerations associated with integrating AI into clinical practice, including data privacy and algorithmic transparency. The discussion extends to the future prospects of AI in prostate cancer care.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
ABOUT THE AUTHOR
Alan Priester is a Data Scientist at Avenda Health, dedicated to developing tools for improved imaging, diagnosis, and focal treatment of prostate cancer. His work, which spans over eight years, has successfully transitioned from bench to bedside, playing a crucial role in surgical planning and minimally invasive prostate cancer treatment. Alan's expertise in image analysis, prototyping, and computer programming enables the rapid development and deployment of biomedical devices.
Alan holds a PhD in Biomedical Engineering from UCLA, where he specialized in image-guided diagnosis and therapy. His comprehensive experience includes developing both hardware and software solutions in collaboration with urologists. His skills in data science, medical imaging, and rapid prototyping are instrumental in advancing the field of prostate cancer treatment.
